Vida Ventures
Venture capitalLos Angeles · Pre-Seed–Late Stage · 35 people tracked
Also known as VIDA VENTURES ADVISORS, LLC · VIDA VENTURES MANAGEMENT CO. LLC · Vida Wealth Partners, Inc.
Investment thesis
Vida Ventures invests in biomedical innovation with the goal of advancing breakthrough science into therapies that make a meaningful difference for patients. The firm emphasizes company creation and value realization in the therapeutics space, backing novel drug programs across areas such as genetic medicines and immunology. Its approach is grounded in core values including patient focus, integrity, entrepreneurship, boldness, humility, collaboration, and flexibility, reflecting a partnership-driven model that supports founders in turning cutting-edge science into clinical-stage medicines.
Source: firm website, verified Aug 3, 2026.
Team · 35 people
from the firm's website & public directories
What they invest in
from 36 of 53 portfolio companiesBiotech ×34Medical Devices ×19Healthtech ×10AI & Machine Learning ×5Digital Health ×4Deep Tech ×3
HQs:United States×32Denmark×1
Investments · 53 tracked
founders shown can be your intro pathAktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.
BiotechHealthtechMedical DevicesBoston, US
Todd Foley(Co-founder and Chairman)Patrick Baeuerle(Co-founder & Advisor)Shulamit Ron-Bigger(Executive Officer)
BoardOleg Nodelman(Director)Andrew Levin(Director)
Board seatHelen S. Kim· per SEC Form D
Therapeutic company focused on validated targets for treating neurological and psychiatric disorders.
BiotechCambridge, US
Nicholas G. Galakatos(Director)Kiran Reddy(Executive Officer, Director)
Board seatStefan Vitorovic· per SEC Form D · $10M raise · filed Jun 2019
BiotechWatertown, US
Timothy Springer(Director)Alise Reicin(Executive Officer, Director)Daniel Lochner(Executive Officer)Marc Schwabish(Executive Officer)Peter McNamara(Executive Officer)Marcella K. Ruddy(Executive Officer)
Board seatStefan Vitorovic· per SEC Form D · $185M raise · filed Feb 2025
Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches.
BiotechHealthtechMedical Devices
ROBERT ABRAHAM(Director)OWEN WITTE(Director)DAVID BONDERMAN(Director)TODD SISITSKY(Director)JOSHUA A. KAZAM(Executive Officer, Director)DAVID M. TANEN(Executive Officer)
Avalyn Pharma develops a nebulized inhalation treatment for pulmonary fibrosis designed to improve tolerability compared to existing oral therapies by directly delivering the drug to the lungs.
BiotechMedical Devices
Lyn Baranowski(CEO)in
Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.
BiotechMedical DevicesWaltham, US
Lawrence Klein, Ph.D.(Director)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)David Lubner(Director)Edward Hurwitz(Director)Dirk Kersten(Director)
LB Pharma develops novel therapies for neuropsychiatric disorders, with a lead product candidate called LB-102, an oral small molecule benzamide antipsychotic targeting schizophrenia, bipolar depression, and other neuropsychiatric diseases.
BiotechDigital Health
Zachary Prensky(Executive Officer, Director)Edmund Sullivan(Director)Vincent Grattan(Director)Lauren Stipp(Executive Officer)Mark Panoff(Executive Officer)
Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.
BiotechMedical Devices
Adcendo develops antibody-drug conjugates (ADCs) engineered to treat cancers with high unmet medical needs.
BiotechDigital HealthMedical Devices<UNKNOWN>, DK
Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Adam Friedman(Chief Executive Officer)in
Agoura Hills, US
Board seatHelen S. Kim· per SEC Form D · $71.6M raise · filed Dec 2022
New York, US
Jesse Horwitz(Executive Officer, Director)Joshua Kazam(Director)Benjamin Cogan(Executive Officer, Director)Eric Osman(Executive Officer, Director)
Board seatJoshua Kazam· per SEC Form D · $500K raise · filed Jan 2018
HealthtechNew York, US
Georg Krause-Vilmar(Executive Officer)Amy Schulman(Director)Hemi Zucker(Director)Guy Oranim(Director)Arie Belldegrun(Director)Anton Linderum(Director)
Board seatArie BelldegrunJoshua Kazam· per SEC Form D · $95.5M raise · filed May 2026
BiotechNew York, US
David Chang(Director, Promoter)Helen Kim(Director)Sean Algeo(Executive Officer, Promoter)Jakob Loven(Director)Mark A. McCamish(Executive Officer, Director)Joshua Kazam(Director)
Board seatHelen S. KimJoshua KazamArie Belldegrun· per SEC Form D · $20.2M raise · filed Jun 2024
BiotechNew York, US
Rebecka Belldegrun, M.D.(Director)Otello Stampacchia, Ph.D.(Director)David M. Tanen(Executive Officer, Director, Promoter)John C. Martin, Ph.D.(Director)Norbert Bischofberger, Ph.D.(Executive Officer, Director)Arie S. Belldegrun, M.D.(Director)
Board seatJoshua Kazam· per SEC Form D
HealthtechNew York, US
Ron Belldegrun(Executive Officer, Director)Georg Krause-Vilmar(Executive Officer)Mia B. Funt(Executive Officer, Director)Devon Kuehn(Executive Officer)Niall Mullane(Executive Officer)Neil Betteridge(Executive Officer)
Board seatArie BelldegrunJoshua Kazam· per SEC Form D · $20.3M raise · filed Jul 2026
BiotechNew York, US
Carsten Linnemann, PhD(Executive Officer, Director, Promoter)David M. Tanen(Director, Promoter)Fei Chen(Director)Antonius N.M. Schumacher(Director)Helen Kim(Director)
Board seatRajul Jain· per SEC Form D · $110M raise · filed Sep 2020
Menlo Park, US
Board seatHelen S. Kim· per SEC Form D · $29.4M raise · filed Oct 2025
New York, US
William Herlands(Executive Officer, Director)Jesse Horwitz(Executive Officer, Director)Drew Tarlow(Director)Joshua Kazam(Director)Rick Heitzmann(Director)Benjamin Cogan(Executive Officer, Director)
Board seatJoshua Kazam· per SEC Form D · $500K raise · filed Jan 2018
New York, US
Ron Belldegrun(Director)Joshua A. Kazam(Director, Promoter)Christopher Wilfong(Executive Officer)David M. Tanen(Director, Promoter)Gregory F. Kiernan(Director, Promoter)Alex Kaufman(Executive Officer, Director)
Board seatJoshua Kazam· per SEC Form D · $6.6M raise · filed Feb 2017
An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Bruce Booth(Director)Ivana Magovcevic-Liebisch(Executive Officer, Director)Christopher Verni(Executive Officer)Mary Thistle(Director)Stefan Vitorovic(Director)Evan Thackaberry(Executive Officer)
Board seatStefan Vitorovic· per SEC Form D
New York, US
Joshua Kazam(Director)Leonard Potter(Director)Brian Levy(Director)Jesse Horwitz(Executive Officer, Director)Benjamin Cogan(Executive Officer, Director)Rick Heitzmann(Director)
Board seatJoshua Kazam· per SEC Form D · $16.5M raise · filed Mar 2017
New York, US
Board seatStefan Vitorovic· per SEC Form D · $15M raise · filed May 2024
A2 Biotherapeutics develops precision CAR T-cell therapies for people with cancer and other diseases using its Tmod cell engineering platform for autologous and allogeneic applications.
BiotechHealthtechAgoura Hills, US
Scott Foraker(Executive Officer, Director)Srini Akkaraju(Director)Madhavan Balachandran(Director)Michael Gallo(Director)David Goeddel(Director)C. Alexander Kamb(Director)
Alterome is a clinical-stage precision oncology company developing small molecule therapies targeting mutant KRAS and AKT E17K in cancers including non-small cell lung, pancreatic, colorectal, endometrial, and breast cancer.
BiotechHealthtechMedical DevicesSan Diego, US
Eric A. Murphy(Executive Officer, Director, Promoter)Thilo Schroeder(Director)Ryan B. Corcoran(Director, Promoter)Carl Gordon(Director)Arjun Goyal(Director)
Attovia develops precision biologics using its ATTOBODY platform for patients with immune-mediated diseases.
BiotechDigital Health
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.
BiotechHealthtechSan Diego, US
Ken Song(Chairman, President and CEO)Kenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)Bernie Huyghe, Ph.D.(Executive Officer)
BoardJeffrey Tong, Ph.D.(Director)
Centessa Pharmaceuticals is developing an Orexin Receptor 2 Agonist program to treat sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders.
BiotechHealthtech
BiotechMedical DevicesNew Haven, US
Scott Phillips(Executive Officer)Tim Shannon(Manager)Liam Ratcliffe(Manager)Leyi Wang(Manager)Rebecca Frey(Manager)
InduPro develops proximity-based therapeutics that manipulate spatial relationships of cell surface proteins to enable new disease treatments.
BiotechDeep TechMedical DevicesSeattle, US
Peloton Therapeutics is a clinical-stage pharmaceutical company developing first-in-class small molecule medicines targeting HIF-2α for cancer and other life-threatening conditions, with initial focus on kidney cancer and VHL disease.
BiotechDigital HealthMedical Devices
Precision Medicine Group provides biomarker-driven research and development services and commercialization support for pharmaceutical and life science companies across drug development, manufacturing, and market access.
BiotechHealthtechMedical Devices
Quanta Therapeutics is developing orally bioavailable KRAS inhibitors for RAS-driven cancers, including candidates targeting KRASG12D, KRASG12V, and pan-KRAS mutations in pancreatic, colorectal, and endometrial cancers.
Biotech
BiotechBoston, US
Adam Friedman(Executive Officer, Director)Andrew Fedder(Executive Officer)Darrin Stuart(Executive Officer)Erica Jackson(Executive Officer)Amanda Valentino(Executive Officer)Gary Glick(Executive Officer, Director)
Soufflé Therapeutics develops nucleic acid medicines that precisely target and deliver genetic therapeutics to specific cell types to treat disease.
AI & Machine LearningBiotechDeep Tech
Victor Kotelianski(Founder)Daniel Anderson(Founder)Robert Langer(Founder)Marino Zerial(Founder)Brad Pentelute(Founder)Amir Nashat(Chief Executive Officer)
Tectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™.
AI & Machine LearningBiotechMedical DevicesWatertown, US
Timothy A. Springer(Co-Founder)Andrew C. Kruse
Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering.
BiotechMedical DevicesLower Gwynedd, US
Joseph Erhardt(Executive Officer)Peter Lebowitz(Executive Officer, Director)
BoardArjun Goyal(Director)Otello Stampacchia(Director)Francesco Draetta(Director)
AbbVie is a biopharmaceutical company that discovers and delivers medicines for immune-mediated diseases and other therapeutic areas globally.
BiotechHealthtechMedical Devices
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Fund performance · per public LP disclosures
as of Jun 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Vida Ventures IILPs: The Regents of the University of California | 2019 | — | 2.1% | 1.08x | 0.63x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Public market activity · per SEC filings
what is this? ⓘ1 insider ownership filing (Forms 3/4/5)
at LB PHARMACEUTICALS INC (LBRX)
Files 13F institutional holdings reports · latest Nov 2025
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- What stage does Vida Ventures invest at?
- Vida Ventures invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Vida Ventures focus on?
- Vida Ventures focuses on Biotech, Deep Tech, Healthtech, Medical Devices.
- Where is Vida Ventures located?
- Vida Ventures is headquartered in Los Angeles, US.
- Does Vida Ventures lead rounds?
- Vida Ventures typically participates in rounds rather than leading them.
Co-investors · 19
Nextech Invest is a Zurich-based investment firm focused on emerging biotechnology companies, backing transformative cancer medicines and precision medicine advances worldwide.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
The Column Group (TCG) is a venture capital firm focused on building and backing biotechnology companies, applying an edge-to-edge investment model centered on company formation with capacity for long-term private and public capital support.
Omega Funds invests in venture capital and growth equity opportunities across the life sciences sector.
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.
Canaan is an early-stage venture capital firm backing founders with transformative ideas across technology and healthcare.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.
ARCH Venture Partners is a venture capital firm that backs and helps build transformational companies, with a strong focus on the life sciences and biotech sector.
Sofinnova is an investment firm that partners with biotech companies from inception through growth, supporting drug development, the regulatory process, company building, and IPO.
Vivo Capital is a global healthcare-focused investment firm operating a multi-strategy platform spanning venture capital, private equity, and public equity. It aims to expand healthcare access and drive innovation through its 'Ecosystem Strategy.'
▶7 more co-investors
Ysios CapitalMedical Excellence CapitalHealthCapNew Enterprise Associates (NEA)General AtlanticJohnson & Johnson Innovation – JJDCVertex Ventures HC
Firms observed investing alongside Vida Ventures, from public investor directories. Shared companies are the overlap with Vida Ventures's recorded portfolio.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.
Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.
Panacea Venture is a global investment firm, spun out from Kleiner Perkins, focused on life sciences and healthcare innovation. It invests across geographies and stages, from company formation through expansion and public markets.